PetMedix secured £27 million in its series B funding round.

PetMedix, a Cambridge UK-based developer of animal health solutions, announced that it raised £27 million ($37M) in Series B funding.

The money was raised from investors led by Tencent and Kyoritsu Holdings, joined by Digitalis Ventures, Parkwalk Advisors and Cambridge Innovation Capital.

Proceeds will be used to advance the company's pipeline through clinical development.

PetMedix, founded in 2017 by Allan Bradley, Jolyon Martin, Thomas Weaver (CEO) provides species-specific therapeutic antibodies to veterinary medicine. The company’s internal discovery programs will continue to advance through development on their way to regulatory approval.